Overview of Trimacare 24%

Property	Description
Active Ingredients	Sulfadiazine, Trimethoprim
Form	Sterile Aqueous Solution for Injection
Pharmacological Class	Potentiated Sulfonamide Antimicrobial
General Purpose	Counteracting bacterial infections
Origin	Synthetic Combination

What Type of Medicine is Trimacare 24% and Its Pharmacological Class?

Trimacare 24% is a specialized synthetic combination product classified as a Potentiated Sulfonamide Antimicrobial, a distinct class of agents developed to address a variety of bacterial infections. The drug entity is composed of the active ingredients Sulfadiazine and Trimethoprim. This specific combination, often referred to as co-trimazine, is clinically recognized for its reliability in managing infections, with its efficacy supported by numerous pharmacological studies. The general purpose of this advanced pairing is to provide a robust broad-spectrum antibacterial defense in scenarios typically involving systemic microbial challenges.

Composition: Sulfadiazine, Trimethoprim, and the 24% Concentration

The material basis of Trimacare 24% is a precise sterile aqueous solution for injection. The quantitative designation 24% refers specifically to the total combined weight-per-volume concentration of the two synthetic active agents in the preparation, formulated at a fixed ratio of 20% Sulfadiazine to 4% Trimethoprim. This composition differs from other similar formulations by being specifically engineered as a high-concentration, injectable form. This form is prepared solely for parenteral administration, a route that ensures rapid and predictable systemic distribution of both Sulfadiazine and Trimethoprim, a defining feature that is often crucial when immediate therapeutic action is required.

General Purpose and the Synergistic Advantage

The core functional purpose of combining these two agents is to achieve a synergistic bactericidal effect, which is substantially more potent than the individual activity of either drug alone. This unique pairing targets the bacteria's essential metabolic pathway—the production of folic acid. By blocking two sequential, critical steps in this pathway, the formulation prevents the bacteria from creating the necessary internal building blocks for their survival and multiplication. This targeted, dual-action mechanism ensures the potent and efficient eradication of susceptible bacteria.

What side effects are possible with Trimacare 24%?

Possible side effects and safety information

Official regulatory documentation classifies potential side effects by frequency and the body system affected, providing a structured overview of the medicine's safety profile.

Frequency-Classified Adverse Reactions

Adverse reactions are categorized according to their official frequency of occurrence:

Very Common (ge 10%): Hyperkalemia (elevated potassium levels).
Common (1% to 10%): Nausea, Diarrhea, Headache, and Fungal/monilial overgrowth.
Very Rare (<0.01%): Severe cutaneous adverse reactions, including Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), as well as serious blood disorders.

System-Organ Classes and Serious Reactions

Adverse events are formally grouped by the body system affected, known as System-Organ Classes (SOCs):

Blood and Lymphatic System Disorders: The label documents the potential for serious hematological disorders, such as Agranulocytosis, Aplastic anaemia, and Thrombocytopenia.
Skin and Subcutaneous Tissue Disorders: Includes the potential for rash, photosensitivity, and life-threatening Severe Cutaneous Adverse Reactions (SCARs) like SJS and TEN.
Gastrointestinal and Hepatobiliary Disorders: Includes common effects like nausea and diarrhea, as well as the documented potential for fulminant hepatic necrosis.
Other SOCs: Adverse effects are also listed under Metabolism and Nutrition Disorders (e.g., hyperkalemia), Nervous System Disorders (e.g., headache, aseptic meningitis), and Renal and Urinary Disorders (e.g., acute renal failure, crystalluria).

Population and Time-Related Safety Constraints

Safety profiles include specific constraints and time-related observations:

Contraindications: Use is contraindicated in infants less than 2 months of age and in individuals with documented severe hepatic or severe renal impairment.
Older Adults: Increased susceptibility to adverse reactions, including severe skin reactions and blood disorders, is officially noted in geriatric patients.
Time Pattern: The risk for certain severe reactions, such as SCARs, is noted to be highest during the first few weeks of starting treatment.

Overdose and Emergency Response

Overdose of Trimacare 24% (Sulfadiazine, Trimethoprim) may present with acute clinical signs such as nausea, vomiting, loss of appetite, confusion, and headache. Documented systemic effects include the appearance of blood in the urine, fever, and jaundice (yellowing of the skin or eyes). Overexposure, especially chronic, can lead to serious laboratory abnormalities, including bone marrow depression, megaloblastic anemia, and hyperkalaemia.

Regulatory authorities mandate that individuals must seek emergency medical attention immediately or contact a poison control service if an overdose is suspected. The official regulatory profile warns of potentially life-threatening outcomes, including severe dermatologic reactions such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), as well as agranulocytosis, acute respiratory failure, and fulminant hepatic necrosis. Due to this risk, the medication must be discontinued immediately upon the first sign of a severe reaction like a rash.

Management is described as symptomatic and supportive, and may involve procedures such as gastric lavage and forced diuresis. Folinic Acid may be administered to counter chronic hematologic toxicity. Special considerations exist for certain populations, including a contraindication for infants less than two months of age and heightened risk for the elderly and those with existing renal or hepatic impairment.

Therapeutic Uses of Trimacare 24%

What Trimacare 24% Treats: Main Uses and Benefits

Trimacare 24% is an antimicrobial therapy commonly used in clinical settings to provide supportive management for severe bacterial infections that require prompt, systemic support. The therapeutic focus is on conditions characterized by periods of heightened symptoms.

The combination is relevant for easing discomfort across a wide range of infections, including urinary tract infections, respiratory tract infections, and systemic conditions relevant in contexts involving heightened systemic burden.

Supportive Relief in Acute Organ-Specific Distress

This medication supports the management of symptoms linked to organ-specific functional stress, including painful urination (dysuria), difficulty breathing due to bacterial involvement, and acute gastrointestinal distress. It is applied in clinical settings that involve acute or unstable symptom patterns, such as severe bacterial pneumonia or complicated urinary tract infections. This provides support that helps ease the overall symptom burden and contributes to easing the overall symptom load during periods of heightened symptoms.

“The medication supports the patient during difficult episodes by easing distress and contributing to improved day-to-day comfort.”

Quick Fact: Relief for Acute Distress
Used for managing symptoms that interfere with daily comfort and lead to temporary functional strain, often when symptoms appear suddenly or fluctuate.

Managing Conditions Requiring Immediate Action

The injectable formulation is particularly relevant in conditions characterized by periods of heightened symptoms where reliable broad-spectrum support is necessary. It is often used during phases when symptoms become more noticeable and may be part of symptomatic management in scenarios where bacterial pathogens are causing acute or disruptive episodes. This approach is applied in settings where short-term symptom stabilization is important and is used in settings where short-term symptomatic assistance is needed.

Regulatory References

NIH StatPearls overview of Trimethoprim Sulfamethoxazole

Eligibility and Restrictions for Use

Who can and cannot use Trimacare 24%

Trimacare 24% is designated as a Veterinary Medicinal Product and its eligibility is strictly defined by regulatory authorities for use in specific target populations.

Approved Populations and Status

The medicine is established for use in Cattle, Pigs, Dogs, Horses, and Cats (target species). Regarding reproductive status, the official regulatory documentation states there are no known contra-indications for use in pregnant and lactating animals.

Absolute Contraindications and Restrictions

Regulatory labels mandate that Trimacare 24% must not be administered to animals with certain pre-existing conditions. Use is contraindicated in animals with a known sulphonamide sensitivity (hypersensitivity to the active ingredients), blood dyscrasias, severe liver parenchymal damage, or seriously impaired renal and/or hepatic function.

Restrictions are also tied to development and intended use: the product is contraindicated in ruminating animals and prohibited for use in horses intended for human consumption. Furthermore, horses exhibiting drug-induced cardiac arrhythmias must not be given the product.

What should I know about interactions with other medicines?

Trimacare 24% Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Trimacare 24% (Sulfadiazine, Trimethoprim) based strictly on government regulatory documents for this drug class.

Interaction-Related Restrictions

Classification	Interacting Product(s)	Basis of Interaction (Regulatory Labeling)
Contraindicated	Dofetilide	High risk of QT interval prolongation and serious ventricular arrhythmias.
Contraindicated	Methenamine	Risk of crystalluria when co-administered with sulfonamides.
Restriction	Alcohol (Ethanol)	Officially documented interaction.

Clinically Significant Interactions

The components of Trimacare 24% interfere with metabolic enzymes (CYP450) and renal transporters (OCT2), affecting the concentration of several co-administered medicines:

Anticoagulants (e.g., Warfarin): Increased anticoagulant effect, resulting in elevated International Normalized Ratio (INR), primarily due to the sulfonamide component inhibiting CYP2C9.
Oral Hypoglycemics (e.g., Pioglitazone, Metformin): Trimethoprim inhibits CYP2C8 and the OCT2 transporter, increasing the blood levels and effects of these medicines.
Digoxin: Documented increases in Digoxin blood levels may occur, an effect that is particularly noted in elderly patients.
Pyrimethamine: Co-administration carries a heightened risk of additive antifolate effects [NIH Label].
ACE Inhibitors/ARBs: Co-use is associated with an additive risk of hyperkalemia.

Mechanism of Action

How Trimacare 24% Works

Trimacare 24% utilizes a synergistic blockade that targets two essential steps in a key microbial metabolic pathway. This mechanism generates a bactericidal physiological effect against susceptible microbes.

Dual-Enzyme Blockade of Folic Acid Biosynthesis

This mechanism targets two distinct enzymes—Dihydropteroate Synthase (DHPS) and Dihydrofolate Reductase (DHFR)—within the susceptible microbe's crucial folic acid synthesis pathway. Sulfadiazine acts as a competitive inhibitor of DHPS, while Trimethoprim inhibits DHFR. The drug combination initiates a sequential blockade of this process, preventing the cell from creating the vital cofactor Tetrahydrofolate (FH4).

Cascade Arrest of Microbial Replication

The consequence of this molecular blockade is the rapid and substantial reduction in the synthesis of DNA and RNA precursors (purines and thymidine) inside the microbial cell. This metabolic starvation prevents the microbe from dividing or replicating its genetic material, which leads to a bactericidal physiological effect.

Dosage and Administration Information

How Trimacare 24% Is Used in Clinical Practice

Trimacare 24% (a high-concentration potentiated sulfonamide solution) is designed exclusively for parenteral administration within a clinical setting, such as a hospital. The medicine is administered solely by slow intravenous (IV) infusion; rapid injection or bolus use is prohibited.

Dosage and Frequency

The dosage for this injectable solution is calculated based on the Trimethoprim (TMP) component, measured in milligrams per kilogram of body weight. For general severe infections, the total daily dose is typically 8 to 10 mg/kg of TMP per day. This total is divided for administration every 6, 8, or 12 hours, depending on the regimen. High-dose regimens, such as those used for Pneumocystis jirovecii pneumonia (PJP), may require up to 15 to 20 mg/kg of TMP daily, divided into multiple doses.

Preparation and Administration

This product is a concentrate and must be diluted prior to use. The concentrate is combined with an approved IV fluid, such as 5% Dextrose in Water. The final solution must be administered via infusion over a period of 60 to 90 minutes to ensure proper delivery. It is an official requirement that the solution must not be mixed with any other medication in the same container or infusion line.

Dosing Adjustments

Official guidelines mandate specific dosage modifications for patients with reduced kidney function. For example, in cases of moderate renal impairment (Creatinine Clearance 15 to 30 mL/min), the dosage is typically reduced to half (50%) of the usual regimen. Furthermore, an adequate fluid intake should be maintained throughout the course of therapy.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Trimacare 24%

Research Evidence for Urinary Tract Infections (UTI)

Research has studied the use of the Trimacare 24% combination (Sulfadiazine and Trimethoprim) in managing Urinary Tract Infections (UTI). The evidence for this indication research describes includes Randomized Controlled Trials (RCTs) and older comparative clinical studies which research examined in adult populations. These trials explored outcomes related to systemic or functional imbalance. Specifically, researchers monitored whether the treatment evaluated whether bacteriological clearance, or bacteriological cure, was observed, and tracked changes in symptoms. Studies conducted during periods of increased symptom activity have reported bacteriological outcome patterns observed following defined time intervals. Evidence is limited for the specific injectable Sulfadiazine/Trimethoprim formulation compared to research available for the closely related oral Sulfamethoxazole/Trimethoprim combination.

Research Evidence for Systemic and Broad-Spectrum Use

The Sulfadiazine/Trimethoprim combination research examined its use for various systemic bacterial infections in research contexts involving fluctuating or unstable symptoms. Because this medicine is an injectable solution, research includes Pharmacokinetic/Pharmacodynamic (PK/PD) studies. These studies research describes how the drug is absorbed and distributed throughout the body, with research showing patterns related to systemic distribution and the achievement of concentrations monitored in research contexts involving fluctuating or unstable symptoms. The evidence often appears to rely on extrapolation of findings from the closely related Sulfamethoxazole/Trimethoprim combination for certain human systemic uses.

Long-Term Studies and Follow-up Durations

The majority of clinical research available for this combination was studied for acute episodes, meaning follow-up durations were limited, typically assessing outcomes within 5 to 14 days of treatment. Evidence exploring long-term symptom changes or the durability of clearance over several months is limited. This means long-term effects are not fully established, and there is limited information for long-term outcomes.

What Remains Unclear About the Research Base

While the combination was studied for its role in conditions associated with acute or disruptive episodes, the evidence quality varies for the different types of studies, and there is a particular reliance on data from the similar, but distinct, Sulfamethoxazole/Trimethoprim combination. Comparative evidence is lacking for the specific injectable Sulfadiazine/Trimethoprim against the newest antibiotics used for acute systemic infections. The evidence highlights what is known—and what is still uncertain—meaning certainty remains low for areas outside the immediate treatment of uncomplicated infections in adults.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Trimacare 24% (FAQ)

Q: What is the main difference between Trimacare 24% and other similar medicines?

Official product information indicates that Trimacare 24% is specifically manufactured as a high-concentration injectable solution. This means it is designed only for parenteral administration (by injection or infusion), unlike similar medicines that may come in oral forms. It is also formulated with a specific, fixed ratio of Sulfadiazine and Trimethoprim.

Q: How quickly do people typically start to feel effects from Trimacare 24%?

Regulatory information for this and similar injectable formulations indicates the medicine is designed for rapid systemic distribution throughout the body. While specific times may vary, professional guidance suggests the onset of therapeutic effects is suggested to occur relatively quickly after administration.

Q: Is Trimacare 24% safe to use long-term?

Clinical studies have primarily focused on treatment for acute episodes, with follow-up durations usually limited to 5 to 14 days. Because of this, official documents often state that long-term effects are not fully established. The potential for adverse effects during prolonged use is a factor for consideration, given the limited long-term data.

Q: Are there any specific foods or drinks that should be avoided when taking Trimacare 24%?

Official documents note that Alcohol (Ethanol) is documented to interact with this medicine, requiring professional guidance for use. Furthermore, the need to maintain adequate fluid intake is noted in the official guidance throughout the course of therapy.

Q: Can Trimacare 24% be taken with blood pressure medication?

Regulatory documents describe the potential for interaction with certain blood pressure medicines, specifically ACE Inhibitors and ARBs. Co-use with these classes of medicines is associated with an increased risk of hyperkalemia (elevated potassium levels).

Q: Can I take Trimacare 24% if I have a history of heart issues?

Official information contraindicates the use of this drug with the anti-arrhythmic medicine Dofetilide, due to the high risk of serious heart rhythm abnormalities. It is also noted that the components may increase Digoxin blood levels, particularly in elderly patients.

Q: Is Trimacare 24% different from similar medicines in how it’s processed by the body?

The components of Trimacare 24% affect certain metabolic enzymes and renal transporters in the body, such as CYP450 enzymes and the OCT2 transporter, which influences the concentration of other co-administered medicines. The injectable route is specifically chosen to ensure rapid and predictable systemic distribution of the active ingredients, which is a defining feature.

Q: Can Trimacare 24% be used by people with diabetes?

Regulatory documents note that the drug can affect the blood levels of some Oral Hypoglycemics (medicines used to treat diabetes) by inhibiting the CYP2C8 enzyme and the OCT2 transporter. This potential for interaction is a factor for consideration.

Q: Is there a maximum time someone is advised to use Trimacare 24%?

The intravenous (IV) formulation is generally intended for short-term use in clinical settings. While the precise maximum duration varies based on the condition being addressed, treatment courses are often restricted to a maximum of approximately 14 days for certain conditions.

Q: Does Trimacare 24% require a prescription in most places?

Yes. According to federal regulations, this injectable veterinary product is restricted to use by or on the order of a licensed veterinarian. This classification ensures that a qualified professional must authorize its administration.

Q: Does Trimacare 24% affect sleep patterns?

The official adverse events profile lists side effects under the Nervous System Disorders class, including headache and, in rare instances for related drugs, aseptic meningitis. While general effects on sleep are not commonly listed, neurological side effects may indirectly affect sleep patterns.

Q: Is it normal to feel tired when first starting Trimacare 24%?

Official frequency classifications do not list general tiredness or fatigue as a common side effect of this medicine. However, tiredness can be a symptom associated with other potential documented side effects, such as low red blood cell levels. These effects are generally monitored during therapy as part of the safety profile.

Q: Why do official documents state Trimacare 24% is only for certain conditions?

The medicine is officially approved for specific bacterial infections. Licensed indications, such as for urinary tract infections (UTI) and systemic infections, are outlined in regulatory documents based on supporting evidence from clinical studies.

Q: Does Trimacare 24% cause weight gain?

Weight gain is not listed among the common or very common side effects in the official frequency classification for this product. Regulatory summaries based on related clinical trials have not specifically identified weight gain as a frequent adverse event.

Q: What is the meaning of the safety classification assigned to Trimacare 24%?

Official regulatory documents classify adverse reactions in two ways: by the frequency of occurrence (e.g., Very Common, Common) and by the System-Organ Class (SOC). SOCs group side effects by the body system they affect, such as Blood and Lymphatic System Disorders or Skin Disorders.

Q: Does Trimacare 24% affect fertility?

The official veterinary label states there are no known contra-indications for use in pregnant and lactating animals.

Q: Does Trimacare 24% interact with birth control pills?

The regulatory labels for this drug class identify potential interactions with medicines used to help prevent pregnancy (contraceptives).

Q: Are there any known issues with taking Trimacare 24% and driving?

Official product documents typically include a section that addresses the drug's effects on the ability to drive and operate machinery. Individuals should be aware that neurological side effects like headache or confusion are noted, which may affect the ability to drive or operate machinery.

Q: Does Trimacare 24% cause changes in mood or behavior?

Adverse effects listed under Nervous System Disorders include effects such as headache. Additionally, regulatory labels for related sulfonamides list rare effects such as mental depression or hallucinations, which are conditions that impact mood and behavior.

Q: Can the effectiveness of Trimacare 24% change over time?

Regulatory documents for antimicrobial agents like this one mention the risk of the emergence of resistance in target bacteria over a course of treatment. If resistance develops, the medicine's efficacy against the infection may be reduced.

How should Trimacare 24% be stored and disposed of?

How to Store and Dispose of Trimacare 24% Solution for Injection

The storage and disposal of Trimacare 24% must strictly follow official regulatory requirements to ensure product stability and safety.

Required Storage Conditions

Condition	Requirement
Maximum Temperature	Store below 25 C
Light Protection	Protect from light
Freezing	Do not freeze
Crystallization	Can be reversed by gentle warming

Stability and Handling

The solution has a shelf life of 28 days after first opening the immediate packaging. Any unused product remaining after this 28-day period must be discarded. The medicine must always be kept out of the sight and reach of children.

Disposal

Unused product and empty containers must be disposed of in accordance with guidance from the local waste regulation authority.

Trimacare 24%